COVAXIN^TM, India^'s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech^'s BSL-3 (Bio-Safety Level 3) high containment facility. The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020. After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXIN^TM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.